Results from A Phase 2 Clinical Trial for Treatment of Bone And Joint Infections with Afabicin, A First-in-Class Selective Anti-Staphylococcal Antibiotic

Alireza Shamaei-Tousi ¹, Moritz Marquardt ¹, Annick Menetrey ¹, Justyna Nowakowska ¹, Justine Dao ¹, David R. Cameron ¹, Charlotte Catala-Goldschmidt ¹,and Ricardo Chaves ¹ ​

^1] Debiopharm International SA, Lausanne, Switzerland